Akebia Therapeutics (NASDAQ:AKBA) executives highlighted a “strong start” to 2026 on the company’s first-quarter earnings ...

"Revenues were nearly $16 million in Q1, representing our highest quarter of Vafseo net product revenue to date" (CEO Butler), and he framed the commercial focus around the TDAPA period in 2026 and ...

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -125.56% and -5.20%, respectively, for the quarter ...

Akebia Therapeutics (AKBA) plummeted more than 20% after reporting a muted Q1 print. It was trading 20.61% lower at $1.18 at noon. The Cambridge, Massachusetts-based firm reported a loss of -$0.03 per ...

Akebia Therapeutics Inc. (AKBA) on Thursday reported a first-quarter loss of $9.1 million, after reporting a profit in the same period a year earlier.

Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us ...

Akebia Therapeutics Inc. (Nasdaq: AKBA) is giving investors optimism due to recent surges and heavy trading activity. In fact, AKBA stock is one of the hottest penny stocks available at the moment.

Detailed price information for Akebia Therapeutics (AKBA-Q) from The Globe and Mail including charting and trades.

Akebia Therapeutics, Inc.AKBA is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing ...

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter.